Michael Murray
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Michael Murray has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
Fabrizio D'ESposito
Pharmacogenomics and Drug Development Group, Faculty of Pharmacy, University of Sydney, NSW 2006, Australia
2 shared publicationsNoelia Nebot
Pharmacogenomics and Drug Development Group, Faculty of Pharmacy, University of Sydney, NSW 2006, Australia
2 shared publicationsPei H Cui
Pharmacogenomics and Drug Development Group, Faculty of Pharmacy, University of Sydney, New South Wales, Australia
2 shared publicationsRobert J. Edwards
Experimental Medicine and Toxicology, Imperial College London, Hammersmith Hospital, United Kingdom
2 shared publicationsWei V. Zhang
Faculty of Pharmacy, University of Sydney, Sydney, Macquarie Hospital, North Ryde and
2 shared publicationsAlison M. Butler
1 shared publication
Latest Publications
- Open Access
- 15 November 2010
- Published by Wiley in British Journal of Pharmacology
- Vol. 162 (5) , 1143-1155
The ω‐3 epoxide of eicosapentaenoic acid inhibits endothelial cell proliferation by p38 MAP kinase activation and cyclin D1/CDK4 down‐regulation
BACKGROUND AND PURPOSE Dietary intake of ω‐3 polyunsaturated fatty acids (ω‐3 PUFAs) like eicosapentaenoic acid (EPA) decreases cancer risk, while arachidonic acid and other ω‐6 PUFAs increase risk, but the underlying mechanisms are unclear. Cytochrome P450 (CYP)‐derived epoxides contribute to enhanced tumourigenesis due to ω‐6 PUFA intake. Thus, ω‐6 arachidonic acid epoxides (EETs) inhibit apoptosis and stimulate proliferation by up‐regulating cyclin D1 expression in cells. The present study evaluated the corresponding ω‐3 PUFA epoxides and assessed their role in the regulation of cell proliferation.EXPERIMENTAL APPROACH Four chemically stable EPA epoxides (formed at the 8,9‐, 11,12‐, 14,15‐ and 17,18‐olefinic bonds) were synthesized and tested against growth‐related signalling pathways in brain microvascular endothelial bEND.3 cells. Cell cycle distribution was determined by flow cytometry and cyclin gene expression by immunoblotting and real‐time PCR. The role of the p38 mitogen‐activated protein (MAP) kinase in cyclin D1 dysregulation was assessed using specific inhibitors and dominant‐negative expression plasmids.KEY RESULTS The ω‐3 17,18‐epoxide of EPA decreased cell proliferation, interrupted the cell cycle in S‐phase and down‐regulated the cyclin D1/cyclin‐dependent kinase (CDK)‐4 complex, whereas the 8,9‐, 11,12‐ and 14,15‐epoxides were either inactive or enhanced proliferation. Cyclin D1 down‐regulation by 17,18‐epoxy‐EPA was mediated by activation of the growth‐suppressing p38 MAP kinase, but the alternate EPA‐epoxides were inactive.CONCLUSIONS AND IMPLICATIONS The present findings suggest that the epoxide formed by CYP enzymes at the ω‐3 olefinic bond may contribute to the beneficial effects of ω‐3 PUFA by down‐regulating cyclin D1 and suppressing cell proliferation.
- 15 November 2010
- Published by Wiley in British Journal of Pharmacology
- Vol. 162 (5) , 1143-1155
Open AccessThe ω‐3 epoxide of eicosapentaenoic acid inhibits endothelial cell proliferation by p38 MAP kinase activation and cyclin D1/CDK4 down‐regulation
BACKGROUND AND PURPOSE Dietary intake of ω‐3 polyunsaturated fatty acids (ω‐3 PUFAs) like eicosapentaenoic acid (EPA) decreases cancer risk, while arachidonic acid and other ω‐6 PUFAs increase risk, but the underlying mechanisms are unclear. Cytochrome P450 (CYP)‐derived epoxides contribute to enhanced tumourigenesis due to ω‐6 PUFA intake. Thus, ω‐6 arachidonic acid epoxides (EETs) inhibit apoptosis and stimulate proliferation by up‐regulating cyclin D1 expression in cells. The present study evaluated the corresponding ω‐3 PUFA epoxides and assessed their role in the regulation of cell proliferation.EXPERIMENTAL APPROACH Four chemically stable EPA epoxides (formed at the 8,9‐, 11,12‐, 14,15‐ and 17,18‐olefinic bonds) were synthesized and tested against growth‐related signalling pathways in brain microvascular endothelial bEND.3 cells. Cell cycle distribution was determined by flow cytometry and cyclin gene expression by immunoblotting and real‐time PCR. The role of the p38 mitogen‐activated protein (MAP) kinase in cyclin D1 dysregulation was assessed using specific inhibitors and dominant‐negative expression plasmids.KEY RESULTS The ω‐3 17,18‐epoxide of EPA decreased cell proliferation, interrupted the cell cycle in S‐phase and down‐regulated the cyclin D1/cyclin‐dependent kinase (CDK)‐4 complex, whereas the 8,9‐, 11,12‐ and 14,15‐epoxides were either inactive or enhanced proliferation. Cyclin D1 down‐regulation by 17,18‐epoxy‐EPA was mediated by activation of the growth‐suppressing p38 MAP kinase, but the alternate EPA‐epoxides were inactive.CONCLUSIONS AND IMPLICATIONS The present findings suggest that the epoxide formed by CYP enzymes at the ω‐3 olefinic bond may contribute to the beneficial effects of ω‐3 PUFA by down‐regulating cyclin D1 and suppressing cell proliferation.
- Open Access
- 16 August 2010
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 70 (3) , 400-408
Impaired irinotecan biotransformation in hepatic microsomal fractions from patients with chronic liver disease
WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT• The anticancer agent irinotecan is a prodrug that is hydrolyzed by hepatic carboxylesterase to its active and toxic metabolite SN‐38 and oxidized by CYP3A4 to its inactive metabolite APC.• Irinotecan therapy is complicated by co‐administered drugs that inhibit CYP3A4 and decrease APC formation and that indirectly increase SN‐38 formation.• Dose adjustment in cancer patients with liver disease has been recommended.WHAT THIS STUDY ADDS• In microsomal fractions from patients with severe hepatic dysfunction both APC and SN‐38 formation were decreased due to down‐regulation of CYP3A4 and carboxylesterase enzymes. Thus relative SN‐38 : APC formation was preserved.• In some fractions the SN‐38 : APC ratio was increased, thus providing a possible explanation for clinical reports of increased SN‐38 exposure in some patients with liver dysfunction.• Close monitoring of SN‐38 formation in patients with severe liver disease is warranted.AIMS: Dose modification with the anticancer agent irinotecan is recommended in patients with severe liver dysfunction. This study evaluated the impact of liver disease on the relative formation of phase I products of irinotecan biotransformation in human microsomesin vitro.METHODS: Microsomes from subjects with normal liver function and liver dysfunction (n = 20) were assessed for irinotecan biotransformation and the expression of cytochrome P450 (CYP) 3A4 and carboxylesterase (CES) enzymes.RESULTS: Liver disease down‐regulated CYP3A4 expression (median 33% of control, range 0–126%,P < 0.05) and impaired CYP3A4‐dependent oxidation of irinotecan to the inactive 7‐ethyl‐10‐[4‐N‐(5‐aminopentanoic acid)‐1‐piperidino]carbonyloxycamptothecin (APC) (median 0.2, range 0–1.21 pmol mg protein−1 min−1compared with median 0.66, range 0–2.35 in control,P < 0.01). CES‐mediated hydrolysis of irinotecan to 7‐ethyl‐10‐hydroxycamptothecin (SN‐38) was also impaired in liver disease (median 8.38, range 0–20.7 pmol mg protein−1 min−1compared with median 13.3, range 0–28.9 in control,P < 0.05). In seven of 20 liver disease microsomes neither metabolite was detected but in three the SN‐38 : APC ratio was high (41–68) compared with the remaining 10 samples (ratio 11–36).CONCLUSIONS: Down‐regulation of CYP3A4 in liver disease decreased APC formation from irinotecan. SN‐38 production was decreased and CES1 and 2 were down‐regulated in most samples. However, in a subset of disease samples SN‐38 production was relatively high because CYP3A4 activity was markedly impaired. This may account for clinical reports of increased SN‐38 exposure in some patients with liver disease. Dose adjustments in cancer patients with liver disease who receive irinotecan are important and circulating SN‐38 concentrations should be monitored closely.
- 16 August 2010
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 70 (3) , 400-408
Open AccessImpaired irinotecan biotransformation in hepatic microsomal fractions from patients with chronic liver disease
WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT• The anticancer agent irinotecan is a prodrug that is hydrolyzed by hepatic carboxylesterase to its active and toxic metabolite SN‐38 and oxidized by CYP3A4 to its inactive metabolite APC.• Irinotecan therapy is complicated by co‐administered drugs that inhibit CYP3A4 and decrease APC formation and that indirectly increase SN‐38 formation.• Dose adjustment in cancer patients with liver disease has been recommended.WHAT THIS STUDY ADDS• In microsomal fractions from patients with severe hepatic dysfunction both APC and SN‐38 formation were decreased due to down‐regulation of CYP3A4 and carboxylesterase enzymes. Thus relative SN‐38 : APC formation was preserved.• In some fractions the SN‐38 : APC ratio was increased, thus providing a possible explanation for clinical reports of increased SN‐38 exposure in some patients with liver dysfunction.• Close monitoring of SN‐38 formation in patients with severe liver disease is warranted.AIMS: Dose modification with the anticancer agent irinotecan is recommended in patients with severe liver dysfunction. This study evaluated the impact of liver disease on the relative formation of phase I products of irinotecan biotransformation in human microsomesin vitro.METHODS: Microsomes from subjects with normal liver function and liver dysfunction (n = 20) were assessed for irinotecan biotransformation and the expression of cytochrome P450 (CYP) 3A4 and carboxylesterase (CES) enzymes.RESULTS: Liver disease down‐regulated CYP3A4 expression (median 33% of control, range 0–126%,P < 0.05) and impaired CYP3A4‐dependent oxidation of irinotecan to the inactive 7‐ethyl‐10‐[4‐N‐(5‐aminopentanoic acid)‐1‐piperidino]carbonyloxycamptothecin (APC) (median 0.2, range 0–1.21 pmol mg protein−1 min−1compared with median 0.66, range 0–2.35 in control,P < 0.01). CES‐mediated hydrolysis of irinotecan to 7‐ethyl‐10‐hydroxycamptothecin (SN‐38) was also impaired in liver disease (median 8.38, range 0–20.7 pmol mg protein−1 min−1compared with median 13.3, range 0–28.9 in control,P < 0.05). In seven of 20 liver disease microsomes neither metabolite was detected but in three the SN‐38 : APC ratio was high (41–68) compared with the remaining 10 samples (ratio 11–36).CONCLUSIONS: Down‐regulation of CYP3A4 in liver disease decreased APC formation from irinotecan. SN‐38 production was decreased and CES1 and 2 were down‐regulated in most samples. However, in a subset of disease samples SN‐38 production was relatively high because CYP3A4 activity was markedly impaired. This may account for clinical reports of increased SN‐38 exposure in some patients with liver disease. Dose adjustments in cancer patients with liver disease who receive irinotecan are important and circulating SN‐38 concentrations should be monitored closely.
- Open Access
- 2 July 2010
- Published by Wiley in British Journal of Pharmacology
- Vol. 161 (5) , 1059-1069
Participation of CYP2C8 and CYP3A4 in the N‐demethylation of imatinib in human hepatic microsomes
BACKGROUND AND PURPOSEImatinib is a clinically important inhibitor of tyrosine kinases that are dysregulated in chronic myelogenous leukaemia and gastrointestinal stromal tumours. Inter‐individual variation in imatinib pharmacokinetics is extensive, and influences drug safety and efficacy. Hepatic cytochrome P450 (CYP) 3A4 has been implicated in imatinib N‐demethylation, but the clearance of imatinib decreases during prolonged therapy. CYP3A phenotype correlates with imatinib clearance at the commencement of therapy, but not at steady state. The present study evaluated the possibility that multiple CYPs may contribute to imatinib oxidation in liver.EXPERIMENTAL APPROACHImatinib biotransformation in human liver microsomes (n= 20) and by cDNA‐expressed CYPs was determined by LC–MS. Relationships between imatinib N‐demethylation and other drug metabolizing CYPs were assessed.KEY RESULTSN‐desmethylimatinib formation was correlated with microsomal oxidation of the CYP3A4 substrates testosterone (ρ= 0.60;P< 0.01) and midazolam (ρ= 0.46;P< 0.05), and the CYP2C8 substrate paclitaxel (ρ= 0.58;P< 0.01). cDNA‐derived CYPs 2C8, 3A4, 3A5 and 3A7 supported imatinib N‐demethylation, but 10 other CYPs were inactive; in kinetic studies, CYP2C8 was a high‐affinity enzyme with a catalytic efficiency ∼15‐fold greater than those of CYPs 3A4 and 3A5. The CYP3A inhibitors ketoconazole and troleandomycin, and the CYP2C8 inhibitors quercetin and paclitaxel decreased imatinib oxidation. From molecular modelling, the imatinib structure could be superimposed on a pharmacophore for CYP2C8 substrates.CONCLUSIONS AND IMPLICATIONSCYP2C8 and CYPs 3A contribute to imatinib N‐demethylation in human liver. The involvement of CYP2C8 may account in part for the wide inter‐patient variation in imatinib pharmacokinetics observed in clinical practice.
- 2 July 2010
- Published by Wiley in British Journal of Pharmacology
- Vol. 161 (5) , 1059-1069
Open AccessParticipation of CYP2C8 and CYP3A4 in the N‐demethylation of imatinib in human hepatic microsomes
BACKGROUND AND PURPOSEImatinib is a clinically important inhibitor of tyrosine kinases that are dysregulated in chronic myelogenous leukaemia and gastrointestinal stromal tumours. Inter‐individual variation in imatinib pharmacokinetics is extensive, and influences drug safety and efficacy. Hepatic cytochrome P450 (CYP) 3A4 has been implicated in imatinib N‐demethylation, but the clearance of imatinib decreases during prolonged therapy. CYP3A phenotype correlates with imatinib clearance at the commencement of therapy, but not at steady state. The present study evaluated the possibility that multiple CYPs may contribute to imatinib oxidation in liver.EXPERIMENTAL APPROACHImatinib biotransformation in human liver microsomes (n= 20) and by cDNA‐expressed CYPs was determined by LC–MS. Relationships between imatinib N‐demethylation and other drug metabolizing CYPs were assessed.KEY RESULTSN‐desmethylimatinib formation was correlated with microsomal oxidation of the CYP3A4 substrates testosterone (ρ= 0.60;P< 0.01) and midazolam (ρ= 0.46;P< 0.05), and the CYP2C8 substrate paclitaxel (ρ= 0.58;P< 0.01). cDNA‐derived CYPs 2C8, 3A4, 3A5 and 3A7 supported imatinib N‐demethylation, but 10 other CYPs were inactive; in kinetic studies, CYP2C8 was a high‐affinity enzyme with a catalytic efficiency ∼15‐fold greater than those of CYPs 3A4 and 3A5. The CYP3A inhibitors ketoconazole and troleandomycin, and the CYP2C8 inhibitors quercetin and paclitaxel decreased imatinib oxidation. From molecular modelling, the imatinib structure could be superimposed on a pharmacophore for CYP2C8 substrates.CONCLUSIONS AND IMPLICATIONSCYP2C8 and CYPs 3A contribute to imatinib N‐demethylation in human liver. The involvement of CYP2C8 may account in part for the wide inter‐patient variation in imatinib pharmacokinetics observed in clinical practice.
- Open Access
- 22 March 2010
- Published by Wiley in British Journal of Pharmacology
- Vol. 159 (7) , 1440-1449
Impaired transactivation of the human CYP2J2 arachidonic acid epoxygenase gene in HepG2 cells subjected to nitrative stress
Background and purpose: Human cytochrome P450 2J2 (CYP2J2) generates epoxyfatty acids that modulate cellular apoptosis and proliferation. CYP2J2 regulation has not been intensively studied but induction of the activator protein-1 (AP-1) subunit c-fos mediates CYP2J2 down-regulation in hypoxia, a component of ischaemic injury. Decreased CYP2J2 expression may contribute to tissue injury. Experimental approach: HepG2 cells were treated with sodium nitroprusside (SNP) to induce nitrative stress, which has been associated with inflammation and infection in liver and other tissues. CYP2J2 protein and mRNA expression were evaluated by immunoblotting and real-time PCR respectively. The role of mitogen-activated protein (MAP) kinases in CYP2J2 dysregulation was assessed using specific inhibitors and dominant negative MAP kinase expression plasmids. CYP2J2-luciferase reporter constructs and electromobility shift assays (EMSAs) were used to identify SNP-regulated regions in the CYP2J2 gene. Key results: Cytochrome P450 2J2 was down-regulated by SNP while the AP-1 proteins c-jun and c-fos were up-regulated; inhibition of p38 and ERK MAP kinases normalized their expression. The gene elements at −105/−95 and −56/−63 were required for the down-regulation of CYP2J2 induced by nitrative stress. Conclusions and implications: p38 and ERK MAP kinases transduce stress stimuli that down-regulate CYP2J2. Targeting these kinases may prevent the loss of CYP2J2 and epoxy-fatty acids that protect cells against deleterious stresses.
- 22 March 2010
- Published by Wiley in British Journal of Pharmacology
- Vol. 159 (7) , 1440-1449
Open AccessImpaired transactivation of the human CYP2J2 arachidonic acid epoxygenase gene in HepG2 cells subjected to nitrative stress
Background and purpose: Human cytochrome P450 2J2 (CYP2J2) generates epoxyfatty acids that modulate cellular apoptosis and proliferation. CYP2J2 regulation has not been intensively studied but induction of the activator protein-1 (AP-1) subunit c-fos mediates CYP2J2 down-regulation in hypoxia, a component of ischaemic injury. Decreased CYP2J2 expression may contribute to tissue injury. Experimental approach: HepG2 cells were treated with sodium nitroprusside (SNP) to induce nitrative stress, which has been associated with inflammation and infection in liver and other tissues. CYP2J2 protein and mRNA expression were evaluated by immunoblotting and real-time PCR respectively. The role of mitogen-activated protein (MAP) kinases in CYP2J2 dysregulation was assessed using specific inhibitors and dominant negative MAP kinase expression plasmids. CYP2J2-luciferase reporter constructs and electromobility shift assays (EMSAs) were used to identify SNP-regulated regions in the CYP2J2 gene. Key results: Cytochrome P450 2J2 was down-regulated by SNP while the AP-1 proteins c-jun and c-fos were up-regulated; inhibition of p38 and ERK MAP kinases normalized their expression. The gene elements at −105/−95 and −56/−63 were required for the down-regulation of CYP2J2 induced by nitrative stress. Conclusions and implications: p38 and ERK MAP kinases transduce stress stimuli that down-regulate CYP2J2. Targeting these kinases may prevent the loss of CYP2J2 and epoxy-fatty acids that protect cells against deleterious stresses.
- 15 October 2009
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 68 (4) , 574-579
In vitroandin vivoevaluation of the inhibition potential of risperidone toward clozapine biotransformation
WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT• The clozapine (CLZ)–risperidone (RISP) combination is effective in schizophrenic patients but may lead to elevated plasma CLZ concentrations and adverse effects.• Reports of potential inhibitory effects of RISP on cytochrome P450 (CYP)‐dependent CLZ oxidation have been inconsistent.• It has been suggested that variations in expression of CLZ/RISP oxidases, such as CYPs 1A2, 2D6 and 3A4, may influence inhibitory interactions.WHAT THIS STUDY ADDS• Inhibition of CLZ biotransformation by RISP was assessed in microsomal fractions that expressed varying amounts of CYPs 1A2, 2D6 and 3A4.• RISP did not inhibit the formation of major oxidized CLZ metabolites, regardless of the CYP expression profile; findings from anin vivostudy in patients were consistent with this finding.• Pharmacokinetic interactions due to the RISP–CLZ combination are unlikely to involve CYPs.AIMS: To study the impact of risperidone (RISP) on clozapine (CLZ) biotransformationin vitroin microsomal fractions containing varying expression of CYP oxidases andin vivoin patients.METHODS: Human liver microsomes (n= 11) were assessed for expression of CYPs 1A2, 2D6 and 3A4, because these enzymes mediate RISP and CLZ oxidation. Inhibition of CLZ oxidation by RISP was assessed. Plasma CLZ elimination was estimated in patients with schizophrenia who received either CLZ alone or the CLZ–RISP combination (n= 10 per group).RESULTS: (i) The CYP3A4 and CYP1A2 inhibitors ketoconazole and fluvoxamine inhibited CLZ oxidation to varying extents in individual microsomal fractions. (ii) RISP did not inhibit CLZ oxidation, regardless of variations in CYP expression. (iii) RISP co‐administration did not impair CLZ clearance.CONCLUSIONS: No evidence was found for CYP‐mediated inhibitory or pharmacokinetic interactions between RISP and CLZ. Occasional literature reports of such interactions may involve other pathways that participate in CLZ disposition.
- 15 October 2009
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 68 (4) , 574-579
In vitroandin vivoevaluation of the inhibition potential of risperidone toward clozapine biotransformation
WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT• The clozapine (CLZ)–risperidone (RISP) combination is effective in schizophrenic patients but may lead to elevated plasma CLZ concentrations and adverse effects.• Reports of potential inhibitory effects of RISP on cytochrome P450 (CYP)‐dependent CLZ oxidation have been inconsistent.• It has been suggested that variations in expression of CLZ/RISP oxidases, such as CYPs 1A2, 2D6 and 3A4, may influence inhibitory interactions.WHAT THIS STUDY ADDS• Inhibition of CLZ biotransformation by RISP was assessed in microsomal fractions that expressed varying amounts of CYPs 1A2, 2D6 and 3A4.• RISP did not inhibit the formation of major oxidized CLZ metabolites, regardless of the CYP expression profile; findings from anin vivostudy in patients were consistent with this finding.• Pharmacokinetic interactions due to the RISP–CLZ combination are unlikely to involve CYPs.AIMS: To study the impact of risperidone (RISP) on clozapine (CLZ) biotransformationin vitroin microsomal fractions containing varying expression of CYP oxidases andin vivoin patients.METHODS: Human liver microsomes (n= 11) were assessed for expression of CYPs 1A2, 2D6 and 3A4, because these enzymes mediate RISP and CLZ oxidation. Inhibition of CLZ oxidation by RISP was assessed. Plasma CLZ elimination was estimated in patients with schizophrenia who received either CLZ alone or the CLZ–RISP combination (n= 10 per group).RESULTS: (i) The CYP3A4 and CYP1A2 inhibitors ketoconazole and fluvoxamine inhibited CLZ oxidation to varying extents in individual microsomal fractions. (ii) RISP did not inhibit CLZ oxidation, regardless of variations in CYP expression. (iii) RISP co‐administration did not impair CLZ clearance.CONCLUSIONS: No evidence was found for CYP‐mediated inhibitory or pharmacokinetic interactions between RISP and CLZ. Occasional literature reports of such interactions may involve other pathways that participate in CLZ disposition.
- 1 May 2009
- Published by Elsevier in Chemistry and Physics of Lipids
- Vol. 159 (1) , 30-37
Synthesis and NMR characterization of the methyl esters of eicosapentaenoic acid monoepoxides
- 1 May 2009
- Published by Elsevier in Chemistry and Physics of Lipids
- Vol. 159 (1) , 30-37
Synthesis and NMR characterization of the methyl esters of eicosapentaenoic acid monoepoxides
- 11 April 2007
- Published by Taylor & Francis in Expert Opinion on Drug Metabolism & Toxicology
- Vol. 3 (2) , 185-196
Role of signalling systems in the effects of dietary factors on the expression of mammalian CYPs
Changes in mammalian diets alter the hepatic expression of CYP drug-metabolising enzymes and endobiotic oxidases. Thus, dietary constituents may significantly influence the duration of action of chemicals in tissues. Recent improvements in the mechanistic information on the regulation of constitutive and inducible expression of CYPs has facilitated our understanding as to how dietary factors modulate expression. Altered regulation appears to occur either by direct activation of transcription factors or by indirect modulation of signal transduction pathways. For example, dietary lipid directly activates PPAR-α, or other nuclear hormone receptors, to elicit CYP induction, and vitamin A deficiency downregulates the growth hormone-responsive CYP2C11 by perturbing Janus kinase-signal transducers and activators of transcription signalling. This article focuses on the present understanding of the regulation of CYP genes by dietary nutrients.
- 11 April 2007
- Published by Taylor & Francis in Expert Opinion on Drug Metabolism & Toxicology
- Vol. 3 (2) , 185-196
Role of signalling systems in the effects of dietary factors on the expression of mammalian CYPs
Changes in mammalian diets alter the hepatic expression of CYP drug-metabolising enzymes and endobiotic oxidases. Thus, dietary constituents may significantly influence the duration of action of chemicals in tissues. Recent improvements in the mechanistic information on the regulation of constitutive and inducible expression of CYPs has facilitated our understanding as to how dietary factors modulate expression. Altered regulation appears to occur either by direct activation of transcription factors or by indirect modulation of signal transduction pathways. For example, dietary lipid directly activates PPAR-α, or other nuclear hormone receptors, to elicit CYP induction, and vitamin A deficiency downregulates the growth hormone-responsive CYP2C11 by perturbing Janus kinase-signal transducers and activators of transcription signalling. This article focuses on the present understanding of the regulation of CYP genes by dietary nutrients.
- 1 December 2006
- Vol. 8 (6) , 480-6
Cytochromes P450: decision-making tools for personalized therapeutics.
The responses of patients to standard drug regimens vary widely, with dose responses ranging from subtherapeutic to toxic. The primary goal of individualized medicine is the optimization of drug therapy, which involves the selection of appropriate drugs, dosages and drug combinations, and the minimization of toxic side effects. The cytochrome P450 (CYP) enzymes mediate the oxidative biotransformation of most drugs, and are important determinants of the duration of drug action. CYPs exhibit a large number of allelic variants that may encode defective enzymes or no enzyme at all. The expression and function of these enzymes are also influenced (induced or inhibited) by non-genetic factors. Patients with diminished CYP capacity may require lower than normal doses of certain drugs, whereas those with an increased metabolic capacity may need higher than normal doses in order to achieve fill efficacy. This review focuses on the recent developments in the field of CYP pharmacogenetics that include characterization of the substrate- and inhibitor-specificity of CYP variant enzymes, and the increasing evidence that polygenic factors influence the design of personalized drug regimens.
- 1 December 2006
- Vol. 8 (6) , 480-6
Cytochromes P450: decision-making tools for personalized therapeutics.
The responses of patients to standard drug regimens vary widely, with dose responses ranging from subtherapeutic to toxic. The primary goal of individualized medicine is the optimization of drug therapy, which involves the selection of appropriate drugs, dosages and drug combinations, and the minimization of toxic side effects. The cytochrome P450 (CYP) enzymes mediate the oxidative biotransformation of most drugs, and are important determinants of the duration of drug action. CYPs exhibit a large number of allelic variants that may encode defective enzymes or no enzyme at all. The expression and function of these enzymes are also influenced (induced or inhibited) by non-genetic factors. Patients with diminished CYP capacity may require lower than normal doses of certain drugs, whereas those with an increased metabolic capacity may need higher than normal doses in order to achieve fill efficacy. This review focuses on the recent developments in the field of CYP pharmacogenetics that include characterization of the substrate- and inhibitor-specificity of CYP variant enzymes, and the increasing evidence that polygenic factors influence the design of personalized drug regimens.
- 1 July 2006
- Published by Oxford University Press (OUP) in Journal of Pharmacy and Pharmacology
- Vol. 58 (7) , 871-885
Role of CYP pharmacogenetics and drug-drug interactions in the efficacy and safety of atypical and other antipsychotic agents
Cytochrome P450 (CYP) drug oxidases play a pivotal role in the elimination of antipsychotic agents, and therefore influence the toxicity and efficacy of these drugs. Factors that affect CYP function and expression have a major impact on treatment outcomes with antipsychotic agents. In particular, aspects of CYP pharmacogenetics, and the processes of CYP induction and inhibition all influence in-vivo rates of drug elimination. Certain CYPs that mediate the oxidation of antipsychotic drugs exhibit genetic variants that may influence in-vivo activity. Thus, single nucleotide polymorphisms (SNPs) in CYP genes have been shown to encode enzymes that have decreased drug oxidation capacity. Additionally, psychopharmacotherapy has the potential for drug-drug inhibitory interactions involving CYPs, as well as drug-mediated CYP induction. Literature evidence supports a role for CYP1A2 in the clearance of the atypical antipsychotics clozapine and olanzapine; CYP1A2 is inducible by certain drugs and environmental chemicals. Recent studies have suggested that specific CYP1A2 variants possessing individual SNPs, and possibly also SNP combinations (haplotypes), in the 5′-regulatory regions may respond differently to inducing chemicals. CYP2D6 is an important catalyst of the oxidation of chlorpromazine, thioridazine, risperidone and haloperidol. Certain CYP2D6 allelic variants that encode enzymes with decreased drug oxidation capacity are more common in particular ethnic groups, which may lead to adverse effects with standard doses of psychoactive drugs. Thus, genotyping may be useful for dose optimization with certain psychoactive drugs that are substrates for CYP2D6. However, genotyping for inducible CYPs is unlikely to be sufficient to direct therapy with all antipsychotic agents. In-vivo CYP phenotyping with cocktails of drug substrates may assist at the commencement of therapy, but this approach could be complicated by pharmacokinetic interactions if applied when an antipsychotic drug regimen is ongoing.
- 1 July 2006
- Published by Oxford University Press (OUP) in Journal of Pharmacy and Pharmacology
- Vol. 58 (7) , 871-885
Role of CYP pharmacogenetics and drug-drug interactions in the efficacy and safety of atypical and other antipsychotic agents
Cytochrome P450 (CYP) drug oxidases play a pivotal role in the elimination of antipsychotic agents, and therefore influence the toxicity and efficacy of these drugs. Factors that affect CYP function and expression have a major impact on treatment outcomes with antipsychotic agents. In particular, aspects of CYP pharmacogenetics, and the processes of CYP induction and inhibition all influence in-vivo rates of drug elimination. Certain CYPs that mediate the oxidation of antipsychotic drugs exhibit genetic variants that may influence in-vivo activity. Thus, single nucleotide polymorphisms (SNPs) in CYP genes have been shown to encode enzymes that have decreased drug oxidation capacity. Additionally, psychopharmacotherapy has the potential for drug-drug inhibitory interactions involving CYPs, as well as drug-mediated CYP induction. Literature evidence supports a role for CYP1A2 in the clearance of the atypical antipsychotics clozapine and olanzapine; CYP1A2 is inducible by certain drugs and environmental chemicals. Recent studies have suggested that specific CYP1A2 variants possessing individual SNPs, and possibly also SNP combinations (haplotypes), in the 5′-regulatory regions may respond differently to inducing chemicals. CYP2D6 is an important catalyst of the oxidation of chlorpromazine, thioridazine, risperidone and haloperidol. Certain CYP2D6 allelic variants that encode enzymes with decreased drug oxidation capacity are more common in particular ethnic groups, which may lead to adverse effects with standard doses of psychoactive drugs. Thus, genotyping may be useful for dose optimization with certain psychoactive drugs that are substrates for CYP2D6. However, genotyping for inducible CYPs is unlikely to be sufficient to direct therapy with all antipsychotic agents. In-vivo CYP phenotyping with cocktails of drug substrates may assist at the commencement of therapy, but this approach could be complicated by pharmacokinetic interactions if applied when an antipsychotic drug regimen is ongoing.
- 1 January 2006
- Published by Bentham Science Publishers Ltd. in Current Drug Metabolism
- Vol. 7 (1) , 67-81
Altered CYP Expression and Function in Response to Dietary Factors: Potential Roles in Disease Pathogenesis
Increasing evidence implicates dietary factors in the progression of diseases, including certain cancers, diabetes and obesity. Diet also regulates the expression and function of CYP genes, which impacts on drug elimination and may also significantly affect disease pathogenesis. Upregulation of CYPs 2E1 and 4A occurs after feeding of experimental diets that are high in fats or carbohydrates; these diets also promote hepatic lipid infiltration, which is a component of the metabolic syndrome that characterises obesity. Increased availability of lipid substrates for CYPs can enhance free radical production and exacerbate tissue injury. Similar processes may also occur in other models of experimental disease states that exhibit a component of altered nutrient utilization. Food-derived chemicals, including constituents of cruciferous vegetables and fruits, modulate CYP expression and the expression of genes that encode cytoprotective phase II enzymes. Certain dietary indoles and flavonoids activate CYP1A expression either by direct ligand interaction with the aryl hydrocarbon receptor (AhR) or by augmenting the interaction of the AhR with xenobiotic response elements in CYP1A1 and other target genes. Other dietary chemicals, including methylenedioxyphenyl (MDP) compounds and isothiocyanates also modulate CYP gene expression. Apart from altered CYP regulation, a number of dietary agents also inhibit CYP enzyme activity, leading to pharmacokinetic interactions with coadministered drugs. A well described example is that of grapefruit juice, which contains psoralens and possibly other chemicals, that inactivate intestinal CYP3A4. Decreased presystemic oxidation by this CYP increases the systemic bioavailability of drug substrates and the likelihood of drug toxicity. Dietary interactions may complicate drug therapy but inhibition of certain CYP reactions may also protect the individual against toxic metabolites and free radicals generated by CYPs. Chemicals in teas and cruciferous vegetables may also inhibit human CYP enzymes that have been implicated in the bioactivation of chemical carcinogens. Thus, food constituents modulate CYP expression and function by a range of mechanisms, with the potential for both deleterious and beneficial outcomes.
- 1 January 2006
- Published by Bentham Science Publishers Ltd. in Current Drug Metabolism
- Vol. 7 (1) , 67-81
Altered CYP Expression and Function in Response to Dietary Factors: Potential Roles in Disease Pathogenesis
Increasing evidence implicates dietary factors in the progression of diseases, including certain cancers, diabetes and obesity. Diet also regulates the expression and function of CYP genes, which impacts on drug elimination and may also significantly affect disease pathogenesis. Upregulation of CYPs 2E1 and 4A occurs after feeding of experimental diets that are high in fats or carbohydrates; these diets also promote hepatic lipid infiltration, which is a component of the metabolic syndrome that characterises obesity. Increased availability of lipid substrates for CYPs can enhance free radical production and exacerbate tissue injury. Similar processes may also occur in other models of experimental disease states that exhibit a component of altered nutrient utilization. Food-derived chemicals, including constituents of cruciferous vegetables and fruits, modulate CYP expression and the expression of genes that encode cytoprotective phase II enzymes. Certain dietary indoles and flavonoids activate CYP1A expression either by direct ligand interaction with the aryl hydrocarbon receptor (AhR) or by augmenting the interaction of the AhR with xenobiotic response elements in CYP1A1 and other target genes. Other dietary chemicals, including methylenedioxyphenyl (MDP) compounds and isothiocyanates also modulate CYP gene expression. Apart from altered CYP regulation, a number of dietary agents also inhibit CYP enzyme activity, leading to pharmacokinetic interactions with coadministered drugs. A well described example is that of grapefruit juice, which contains psoralens and possibly other chemicals, that inactivate intestinal CYP3A4. Decreased presystemic oxidation by this CYP increases the systemic bioavailability of drug substrates and the likelihood of drug toxicity. Dietary interactions may complicate drug therapy but inhibition of certain CYP reactions may also protect the individual against toxic metabolites and free radicals generated by CYPs. Chemicals in teas and cruciferous vegetables may also inhibit human CYP enzymes that have been implicated in the bioactivation of chemical carcinogens. Thus, food constituents modulate CYP expression and function by a range of mechanisms, with the potential for both deleterious and beneficial outcomes.